About this trial
The worldwide incidence of placenta accreta spectrum is increasing, following the trend of rising caesarean delivery. It is an heterogeneous condition associated with a high maternal morbidity and mortality rate (Jauniaux et al., 2018).
caesarean hysterectomy is considered the gold standard for the treatment of placenta accreta. Also this radical approach is associated with high rates of severe maternal morbidity as hemorrhage and insult to surrounding organs during surgery (Hoffman et al., 2010).
Surgeons should be able to dissect the bladder safely and confidently through minimally invasive techniques, to avoid surgical injury, it is important to use anatomic landmarks, minimize the use of cauterization (Farhat and Casale, 2018).
All centers are encouraged to develop guidelines to manage the potential urologic complications of these cases tailored to their resources (Taneja and Shah, 2017).
This study aims to evaluate the timing of bladder dissection in caesarean section in patient with placenta accreta spectrum.
Eligibility criteria
Qualifiers
Women with BMI at or under 35kg/m2
Women with history of at least previous two caesarean section
Gestational age more than 32 weeks with viable fetus.
Women with any degree of placenta previa.
Disqualifiers
o History of urinary bladder injury.
History of urinary or renal disorders
Women with coagulation disorders or on anticoagulation therapy.
Patients who are hemodynamically unstable before skin incision
Trial design
Treatments tested in this trial
- bladder dissection in placenta accreta spectrum